Johnson & Johnson’s HIV vaccine fails mid-stage study

Johnson & Johnson's HIV vaccine

54

Last Updated on September 1, 2021 by The Health Master

Johnson & Johnson said on Tuesday its experimental vaccine failed to provide enough protection against HIV in sub-Saharan Africa to young women who are at high risk of being infected.

The mid-stage trial failure highlights the challenges of vaccine development, especially for HIV or human immunodeficiency virus, which has no approved vaccines.

HIV is a unique and complex virus that has long posed unprecedented challenges for vaccine development because of its ability to attack, hijack and evade the human immune system,” Paul Stoffels, Johnson & Johnson ‘s chief scientific officer, said in a statement.

The study testing the vaccine included the participation of 2,600 women across five Southern African countries, where women and girls accounted for over 60% of all new HIV infections last year.

Medicine Injection drug vaccine
Picture: Pixabay

The trial of the vaccine, which is based on the adenovirus design which Johnson & Johnson ‘s C-19 vaccine also uses, was supported by the U.S. the National Institute of Allergy and Infectious Diseases and the Bill & Melinda Gates Foundation.

The study will not continue, based on the data, Johnson & Johnson said. Participants in the study will be informed about the results and told whether they received a placebo or the vaccine.

Johnson & Johnson said it is studying the safety and efficacy of a different composition of the vaccine regimen among men who have sex with men and transgender persons.

Indian Pharma exports: Oceania a potential region: Pharmexcil

Drug recall: Dr Reddy’s & Zydus Pharma Recall these drugs

DCGI approves 3 FDCs containing Cefixime & Cefadroxil as rational

CDSCO issues procedure for regulation of 19 FDCs out of 294

Novel antibiotic Nafithromycin for respiratory track infection

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news

Enter your email address:

Delivered by FeedBurner